58502-69-5

Upstream product

• 563-70-2 bromonitromethane 
• 100-52-7 benzaldehyde 
• 5153-67-3 nitrostyrene 
• 102-96-5 (2-nitroethenyl)benzene 

Downstream Products

• 33184-20-2 3-phenyl-4H-furo<3,2-c><1>benzopyran-4-one 
• 133116-26-4 2,3-dihydro-2-nitro-3-phenyl-4H-furo<3,2-c><1>benzopyran-4-one 
• 69960-21-0 1,4-Dihydroxy-2-(1-phenyl-ethyl)-anthraquinone 
• 132784-81-7 6,6-dimethyl-2-nitro-3-phenyl-3,5,6,7-tetrahydro-4(2H)-benzofuranone 
• 141764-36-5 5-phenylfuro<2,3-d>pyrimidin-4(3H)-one 
• 141764-35-4 5,6-dihydro-6-nitro-5-phenylfuro<2,3-d>pyrimidin-4(3H)one 
• 187585-47-3 3,6-Dinitro-2-phenyl-chromen-4-one 
• 163977-84-2 3-nitro-2-phenyl-8-(prop-2-enyl)-4H-1-benzopyran-4-one 

Relevant academic research and scientific papers

Chlorination of Conjugated Nitroalkenes with PhICl 2and so 2Cl 2for the Synthesis of α-Chloronitroalkenes

Chlorination of conjugated nitroalkenes with iodobenzene dichloride or sulfuryl chloride to give target α-chloronitroalkenes in good yields is described. Details of the procedure depend on the donating ability of the nitroalkene substituents. The activity of the described chlorinating agents increases in order 'PhICl 2/Py' 2Cl 2' 2Cl 2/HCl' with the former producing the best yields for highly donating substrates and the latter for non-activated groups. An autocatalytic role of hydrogen chloride and the chemoselectivity of chlorination were also demonstrated.

Biological evaluation and SAR analysis of novel covalent inhibitors against fructose-1,6-bisphosphatase

Fructose-1,6-bisphosphatase (FBPase) is an attractive target for affecting the GNG pathway. In our previous study, the C128 site of FBPase has been identified as a new allosteric site, where several nitrovinyl compounds can bind to inhibit FBPase activity. Herein, a series of nitrostyrene derivatives were further synthesized, and their inhibitory activities against FBPase were investigated in vitro. Most of the prepared nitrostyrene compounds exhibit potent FBPase inhibition (IC50 3, CF3, OH, COOH, or 2-nitrovinyl were installed at the R2 (meta-) position of the benzene ring, the FBPase inhibitory activities of the resulting compounds increased 4.5–55 folds compared to those compounds with the same groups at the R1 (para-) position. In addition, the preferred substituents at the R3 position were Cl or Br, thus compound HS36 exhibited the most potent inhibitory activity (IC50 = 0.15 μM). The molecular docking and site-directed mutation suggest that C128 and N125 are essential for the binding of HS36 and FBPase, which is consistent with the C128-N125-S123 allosteric inhibition mechanism. The reaction enthalpy calculations show that the order of the reactions of compounds with thiol groups at the R3 position is Cl > H > CH3. CoMSIA analysis is consistent with our proposed binding mode. The effect of compounds HS12 and HS36 on glucose production in primary mouse hepatocytes were further evaluated, showing that the inhibition was 71% and 41% at 100 μM, respectively.

PhICl2 and wet DMF: An efficient system for regioselective chloroformyloxylation/a-chlorination of alkenes/a,β-unsaturated compounds

PhICl2 in wet DMF was found to form an efficient system for realizing difunctionalization of various alkenes and olefinic derivatives possessing a wide range of functional groups. This novel methodology provides convenient access to either regioselective chloroformyloxylated products or a-chlorinated olefinic products, depending on the type of structure of the original unsaturated starting material. The mechanism of the reaction is proposed and discussed.

FURANOPYRIMIDINES

The present invention relates to furanopyrimidine compounds having the general Formula (I) and stereoisomers, tautomers, solvates, pharmaceutically acceptable salts and derivatives, and prodrugs thereof. The invention also includes pharmaceutical compositions comprising a compound of Formula (I), methods of treating various diseases and conditions in a mammal, including inflammation, inhibition of T cell activation, proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma and thymoma, comprising administering to the mammal a therapeutically effective amount of a compound of Formula (I). The invention also relates to methods of manufacturing medicaments, which comprise one or more compounds of Formula (I).

An expedient synthesis of β-chloro-β-nitroolefin derivatives

β-Chloro-β-nitroolefin derivatives 2 were prepared from the reaction of β-nitroolefins 1 with HCl/DMF/Oxone system in moderate to good yields.

A Convenient Synthesis of 3-Chloro-3,4-dihydro-4-hydroxy-3-nitro-2-phenyl-2H-1-benzopyrans

The novel title compounds 5 are prepared by a simple and efficient two-step procedure starting from substituted benzaldehydes 1.A convenient route to the (2-chloro-2-nitroethenyl)benzenes 3 required as intermediates in the synthesis is reported.